Based on the Zoetis Inc stock forecast from 8 analysts, the average analyst target price for Zoetis Inc is USD 210.75 over the next 12 months. Zoetis Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Zoetis Inc is Slightly Bullish , which is based on 9 positive signals and 6 negative signals. At the last closing, Zoetis Inc’s stock price was USD 195.71. Zoetis Inc’s stock price has changed by +2.27% over the past week, +6.53% over the past month and +8.58% over the last year.
No recent analyst target price found for Zoetis Inc
No recent average analyst rating found for Zoetis Inc
Company Overview Zoetis Inc
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey. Read Less
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including lives...Read More
Frequently Asked Questions About Zoetis Inc (ZTS) Stock
Based on ratings from 8 analysts Zoetis Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 12 buy, sell and hold ratings.
ZTS stock's dividend yield is 0.94%.
Our analysis grades ZTS stock's dividend yield at F. This means that ZTS stock's dividend yield is above 50% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NYE exchange.
Based on this ZTS may be a average dividend stock for its sector.
Based on targets from 8 analysts, the average taret price for ZTS is USD 210.75 over the next 12 months. The maximum analyst target price is USD 248 while the minimum anlayst target price is USD 180.
ZTS stock's Price/Earning ratio is 35.99.
Our analysis grades ZTS stock's Price / Earning ratio at D+. This means that ZTS stock's Price/Earning ratio is above 32.99999999999999% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NYE exchange.
Based on this ZTS may be fairly valued for its sector
The last closing price of ZTS's stock was USD 195.71.
The most recent market capitalization for ZTS is USD 83.17B.
Based on targets from 8 analysts, the average taret price for ZTS is projected at USD 210.75 over the next 12 months.
This means that ZTS's stock price may go up by +7.68% over the next 12 months.
We can't find any ETFs which contains Zoetis Inc's stock.
As per our most recent records Zoetis Inc has 14,100 Employees.
Zoetis Inc's registered address is 10 Sylvan Way, Parsippany, NJ, United States, 07054.
You can get more information about it from Zoetis Inc's website at https://www.zoetis.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Dividend Growth
This stock has shown below median dividend growth in the previous 5 years compared to its sector.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Zoetis Inc (ZTS) Stock
Based on ratings from 8 analysts Zoetis Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 12 buy, sell and hold ratings.
ZTS stock's dividend yield is 0.94%.
Our analysis grades ZTS stock's dividend yield at F. This means that ZTS stock's dividend yield is above 50% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NYE exchange.
Based on this ZTS may be a average dividend stock for its sector.
Based on targets from 8 analysts, the average taret price for ZTS is USD 210.75 over the next 12 months. The maximum analyst target price is USD 248 while the minimum anlayst target price is USD 180.
ZTS stock's Price/Earning ratio is 35.99.
Our analysis grades ZTS stock's Price / Earning ratio at D+. This means that ZTS stock's Price/Earning ratio is above 32.99999999999999% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NYE exchange.
Based on this ZTS may be fairly valued for its sector
The last closing price of ZTS's stock was USD 195.71.
The most recent market capitalization for ZTS is USD 83.17B.
Based on targets from 8 analysts, the average taret price for ZTS is projected at USD 210.75 over the next 12 months.
This means that ZTS's stock price may go up by +7.68% over the next 12 months.
We can't find any ETFs which contains Zoetis Inc's stock.
As per our most recent records Zoetis Inc has 14,100 Employees.
Zoetis Inc's registered address is 10 Sylvan Way, Parsippany, NJ, United States, 07054.
You can get more information about it from Zoetis Inc's website at https://www.zoetis.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ZTS !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
